ストックスクリーナーアプリを入手
2.88
6.80%
-0.21
アフターアワーズ：
2.87
-0.010
-0.35%
Lexaria Bioscience Corp (LEXX) 最新ニュース
Lexaria Bioscience (LEXX) pays $402K in warrant fees - Stock Titan
Lexaria Extends Cash Runway Through 2027 After $7.9 Million Capital Boost - TipRanks
Lexaria Bioscience Corp (NASDAQ: LEXX) Share Price, LEXX Stock News, LEXX Share Price & Updates - kalkine.com.au
Lexaria DHT3.0 boosts oral absorption for amycretin and retatrutide - scanx.trade
Lexaria Bioscience raises $7.9M, extends cash runway to 2027 By Investing.com - Investing.com Australia
Lexaria Bioscience secures $7.9M to extend cash runway through 2027 - scanx.trade
Lexaria Bioscience raises $7.9M, extends cash runway to 2027 - Investing.com
Lexaria Updates Financial Position - Weatherford Democrat
Lexaria Bioscience Corp. (NASDAQ:LEXX) Adds $7.9M Cash, Guides Runway Through 2027 - TradingView
Lexaria Bioscience Corp. (NASDAQ:LEXX) Adds $7.9M, Runway Through 2027; No 2026 Financing Planned - TradingView
Lexaria Bioscience Corp.Common Stock (NQ: LEXX - The Chronicle-Journal
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - Investing News Network
$5.9 million raised as Lexaria issues new rights to buy shares - Stock Titan
Lexaria Raises $5.9M in Warrant Exercise Transaction - Minichart
Lexaria Bioscience Raises $5.9 Million Via Warrant Exercise; Issues New Warrants, Engages Wainwright - TradingView
Primer: Lexaria Bioscience (LEXX US)Sep 2026 - Smartkarma
Lexaria Raises $5.9 Million Via Warrant Exercise and Issues New Warrants - TipRanks
Lexaria raises $5.9M by exercising warrants at reduced price to fund 2027 operations and R&D. - Pluang
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds - investingnews.com
Lexaria Announces Exercise of Warrants For Approximately $5.9 Million in Gross Proceeds - TradingView
A potential $5.9 million plus a $2.6 million rebate may fund Lexaria's 2027 research - Stock Titan
LEXX: Introducing DehydraTECH 3.0 - Yahoo Finance
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Investing News Network
Lexaria to present at H.C. Wainwright Global Investment Conference in September 2026 - Pluang
A drug-delivery company holds 66 granted patents. Lexaria plans a New York presentation. - Stock Titan
Lexaria Bioscience Corp. (LEXX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexaria Bioscience: Advancing Next-Generation Oral Weight-Loss Drugs - The Globe and Mail
LEXX Looks 131.9% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience advances 12% on Australian tax rebate (LEXX:NASDAQ) - Seeking Alpha
Lexaria enters MTA with PegBio to test GLP-1 delivery tech - scanx.trade
LEXX Looks 129.0% Overvalued on GF Value™ - GuruFocus
Lexaria advances GLP-1 partnerships at BIO 2026 - scanx.trade
Lexaria Bioscience Receives Australian R&D Tax Incentive Credit - TipRanks
LEXX Looks 117.5% Overvalued on GF Value™ - GuruFocus
Lexaria receives $2.6 million Australian R&D tax rebate By Investing.com - Investing.com South Africa
Lexaria Bioscience receives AUD$3.67m Australian tax rebate - scanx.trade
Lexaria receives $2.6 million Australian R&D tax rebate - Investing.com
Lexaria nets $2.6M Australian tax rebate to fun... - Pluang
Lexaria Bioscience receives AUD 3.67M Australian R&D tax credit to fund clinical RD - TradingView
Lexaria Receives USD$2.6 Million Tax Rebate Payment - ncnewsonline.com
Lexaria DehydraTECH 3.0 Boosts GLP-1 Drug Absorption in 2026 Study - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed By Investing.com - Investing.com India
Form 8K LEXARIA BIOSCIENCE CORP. For: 17 August By Investing.com - Investing.com Nigeria
Lexaria Bioscience Regains Nasdaq Compliance, Stabilizing Listing - TipRanks
Lexaria Bioscience regains Nasdaq compliance, stock to remain listed - Investing.com
Lexaria Bioscience regains Nasdaq bid-price compliance, listing continued - TradingView
Delisting risk eases as Lexaria (NASDAQ: LEXX) regains bid-price compliance - Stock Titan
Lexaria Bioscience enters MTA with PegBio - TipRanks
LEXX Looks 64.3% Overvalued on GF Value™ - GuruFocus
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know - Benzinga
Lexaria Signs PegBio Deal to Test DehydraTECH With GLP-1 Diabetes Drug - TipRanks
Lexaria Bioscience Corp. Enters Material Transfer Agreement with Pegbio Co., Ltd - marketscreener.com
0.05%
0.82%
大文字化:
|
ボリューム (24 時間):